Member Info for HereforHemo

Micky there's no doubt they'll be a heavy discount of the next raise, in real terms SP at 0.5 I would think, but there's others who know far more than me.

I think LOTM summed it up perfectly with this...

The only problem with your thought's is that HEMO is not going to get a near 90% increase in market cap raise away at £4 per share.

If you go back & take the share price from thursday's close. Those long term shareholders & anyone else who didn't sell immediately are already down 20%. For them to suffer no dilution the placing would need to be at £6 which isn't going to happen.

I highly doubt they would get that sort of size of a raise away at £3 per share.

Lets say for arguments sake that they got that $20M (& I'm not in any way saying they will) & had 9 million shares in issue afterwards. That would mean existing shareholders are left owning only @ 39% of the company at that price, on Thursday's closing price its significantly more than that, they would still have had around 58% ( 3.5M of the 6M in issue [2.5M new x£6 = £15M ] ) . They have been greatly diluted & the worst affected are the long term shareholders. If they want to average down a bit it costs them more & more to do so each time.

And it's even more frustrating if you consider it wasn't the shorters who totalled the SP to 1p raises, it was Vlad with his death spiral Mint CLN's, when he'd had numerous opportunities to raise at 7p.

My ultimate take is this isn't a share for Mr average. There is going to be more heavy dilution. With 18 patients Phase 1 will last well over a year and I don't think Vlad will be looking at selling anything until they're into Phase 2.

If you can take a long term view and if you have the odd £75-150k to invest you'll probably make a lot of money in the years to come. If you're a small investor like me it's a lesson learnt.

Out of the last 25 posts I've had 15 green boxes and 9 posts talking about them, so not a lot of value to be had.

But there is a lesson to be had. Whilst some refer to charts with regard to future performance, what I've found over the years gone by, and I don't really understand why, is that every single time (and I do really mean every time) this has happened to a share I hold there has been major transformational news that followed shortly after.

Have a great weekend all.

Billy the reasons I hold are as follows:

There are 15 development wells to be drilled in the states, the first 6 funding the additional 9 and these are expected to generate approx $15m in revenue over the next 5 years.

We are on the verge of a Mining License being approved and developing around 30 production wells for the southern Rukwa Project that will undoubtedly bring in a major partner, either offtake, JV or both.

People saying volumes are a guess, but not really. Tai HAS had a CPR, totally independent. Anywhere between 2.8 and 7.1 Billion Cubic Feet of helium. But let’s take the mean average of 4.0 Bcf. That alone makes this commercial with anywhere between $1.2 and $4 billion of helium, depending on where it is sold and to who.

Then we have Itumbula. Continuous helium from surface to basement flowing at over 7% concentration. With multiple faults and fractures, comments like ‘it’s of global significance’ it’s safe to assume it’s at least as big as Tai, so again taking a mean average we’re talking a total of $8 Bcf, generating anywhere between $2.4 and $8 billion revenue. Plus the rest of the project to include.

That’s my take anyway. Not bothered who’s selling at the moment as I’m continuing to buy bringing my average down nicely.

Each to their own.

Don’t want to talk down my ‘investment’ but I will.

Don’t you just love honesty lol.

Thank god transformation news is very close and we can be rid of these muppets once and for all.

Pub if you add strategic majors wanting to get involved in Tanzania coupled with an estimated $15m worth of revenue coming from America, I’d say with a little patience it’s a compelling opportunity.

IslandGirl If memory serves the last presentation stated 18 patients, not sure if that’s still the plan?

Whilst I get the frustration with the current SP I am absolutely sure it will not remain at this lowly level for long.

The downside is over, there’s money in the bank with a long financial runway.

Furthermore there’s 15 development wells to be drilled in the states all fully funded (the first 6 funding the other 9). Then we are a producer generating approximately $3m per annum revenue.

That’s before the globally significant Tanzanian project. A Mining License, confirmation of how many billion cubic feet they believe there is, an offtake and or JV with a major and the development plan for around another 30 development wells.

Everything starts next month so barely a week or so before things will start to look brighter.

Keep calm during the storm and be patient, the sun is about to shine.

‘The commission has also been connecting small scale miners to financial institutions’ https://www.tanzaniainvest.com/mining/mining-commission-licenses-2018-2024

Https://www.proactiveinvestors.co.uk/companies/news/1061071/helium-one-reports-on-its-exciting-and-transformational-year-as-projects-advance-1061071.html?rel=scroll

VAT refund due $2.3m, even better

Blubay I think the VAT refund is around $1.3m to add to the balance. There was another $1.1m less costs added from Galactica and personally I think as well as adding contingency they’ve allocated more than required for each drill in the US.

All in all they are in very good shape.

Why keep a thread going with a troll? It’s clear who’s invested and who’s not. Just filter or ignore them rather than clog up the board.

It’s not only the resources and ML confirmation that will derisk He1. Do not underestimate the biggest risk to explorers, that’s a lack of revenue. A massive tick in the box for HE1, revenues from Q2.

Https://rarediseases.org/wp-content/uploads/2021/03/orphan-drugs-in-the-united-states-NRD-2020.pdf

Confirms what I and many have constantly said. All activities in America are fully funded and enough cash in the bank to get them through to the end of Q2 where they will begin to generate revenues of $2-3m pa from the Galactica project.

I understand Hemogenyx will apply for Orphan Drug Status upon commencing the CAR-T trial.

The FDA grants orphan drug designation to drugs and biologics that meet certain criteria and are intended to treat, prevent, or diagnose rare diseases:

What is an orphan disease?

A rare disease or condition that affects fewer than 200,000 people in the United States. Orphan diseases are often serious or life threatening.

What are the benefits of orphan drug designation?

Sponsors of orphan drugs receive incentives such as:

Tax credits for qualified clinical trials

Exemption from user fees

Potential for seven years of market exclusivity after approval

How does the FDA support orphan drug development?

The FDA also:

Established the Orphan Product Grants Program to provide funding for developing products for rare diseases Awards grants to provide funding for clinical trials.

Pub he’s another muppet from HEX, probably bored of waiting another 2 years to see if they can get anything commercial out of their pile of shale.

Ginger these are the hospitals:

https://www.england.nhs.uk/commissioning/spec-services/advanced-therapy-medicinal-products/car-t-therapy/#:~:text=The%20NHS%20is%20providing%20CAR,B%2Dcell%20lymphoma%20in%20England

Ginger I understand certain hospitals have now struck a deal where CAR-T will be provided at a tenth of the cost of therapy in the USA. Good luck! https://www.england.nhs.uk/2023/04/nhs-to-roll-out-personalised-car-t-cancer-therapies-to-hundreds-more-people/